Top Tweets for #GetDCVAX
#FreezeYourTumor
#GetDCVax
#QualityOfLifeMatters
💪💪💪💪💪💪
Northwest Biotherapeutics stock: Takeover bomb explodes!
$nwbo #dcvax #glioblastoma #gbm
https://t.co/4yUzkTRk1y

"The 2nd chart shows unpublished results on a combination for recurrent #GBM that will likely get a quick approval under PPA but has been working on the regular approval pathway for over 20 years now."
#FreezeYourTumor
#GetDCVax
#QualityOfLifeMatters
$nwbo #dcvax #glioblastoma

@alphavestcap @ATLnsider @metacollectiveG @BrianEgolf2 Isn’t the same KM curves we’ve seen from this trial before? The very very interesting new bit is the written commentary.
Brain Tumour Research @braintumourrsch has several very encouraging stories on DCVax-L.
👏
#FreezeYourTumor
#GetDCVax
#QualityOfLifeMatters
👍
The DCVax® Platform For All Solid Tumor Cancers
💪
$nwbo #dcvax #glioblastoma #gbm
https://t.co/4sLIea4JTD
https://t.co/LuYhHVyjoU

October 2025
Evernorth Gene Therapy Pipeline
Watch List
#FreezeYourTumor
#GetDCVax
#QualityOfLifeMatters
👍
The DCVax® Platform For All Solid Tumor Cancers
💪
$nwbo #dcvax #glioblastoma #gbm #NonToxic #CancerAwareness #Cancer
https://t.co/ItGTepZ3xw
https://t.co/FzWg6RjWMs

Matt only got limited doses of $nwbo #DCVax-L because his #gbm #glioblastoma tumor wasn't stored properly.
💔
He believes the vaccine prolonged his life & hopes to see it approved by NHS.
🙏
Godspeed Matt.
#FreezeYourTumor
#GetDCVax
#QualityOfLifeMatters
https://t.co/vIbWelVqLz

While we remember those that have passed from #gbm, let's also celebrate LONG TERM SURVIVORS that got #NonToxic #DCVax-L for #glioblastoma. Many are alive & well a DECADE+ and a few now beyond 20 YEARS with NO RECURRENCE! $nwbo
👏
#FreezeYourTumor
#GetDCVax
#QualityOfLifeMatters
May is #BrainCancerAwarenessMonth. Let's celebrate long term survivors who received #DCVax-L for #glioblastoma. Reply to this post with their story.
$nwbo #gbm
I'll start:
Jamil Newirth, 13 years and still no recurrence! Attorney & now pickleball player.
https://t.co/X3NR2XogsI

Sept 29, 2025:
DCVax-L increased the 4-year survival rate to 15.7% in the nGBM cohort v 9.9% in controls. In the rGBM cohort the #DCVax-L group showed a significantly higher mOS (13.2 m vs. 7.8 m).
💪
#FreezeYourTumor
#GetDCVax
$nwbo #glioblastoma #gbm
https://t.co/c3XeKr7bGQ

Not sure when the status changed for the #DCVax-L #Keytruda trial, but it's now no longer Recruiting, and is instead Active, Not Recruiting. All slots must have been filled.
#FreezeYourTumor
#GetDCVax
#QualityOfLifeMatters
🙏
$nwbo $mrk #glioblastoma #gbm
https://t.co/QETgHHL6zW

@FlemmingBruce @d_stock07734 mRNA-5671 / Keytruda combo trial was "Terminated" for "Business Reasons".
OTOH, DCVax-L / Keytruda combo still "Recruiting".
#FreezeYourTumor #GetDCVax
$nwbo #dcvax #glioblastoma #gbm #NonToxic #CancerVaccine #ForAllSolidTumors
https://t.co/j772yUk27M
https://t.co/6ec5NtE5G8

September 22, 2025
Won Kim , MD - UCLA
https://t.co/OCmyeDHBsQ
https://t.co/9qSiliA0fD
#FreezeYourTumor
#GetDCVax
#QualityOfLifeMatters
🙏
$nwbo #dcvax #glioblastoma #gbm

The great news about DCVax®-L personalized vaccine is that so many patients are alive & well with little to no side effects. They can tell their own stories!
🫶
#FreezeYourTumor
#GetDCVax
#QualityOfLifeMatters
$nwbo #dcvax #glioblastoma #gbm
https://t.co/YLn5dK7rav
@RichFairgrieve @Richard67637214 Without $NWBO #DCVAX @UCLA the brilliant Drs Liau, Prins, & Chong, amazing staff, long investors, genius company & warrior DCVAX survivors like @ThomasOwenMcCa1, my husband would be facing certain death. Now, we're excited about our daughter's upcoming wedding.
MONTHS👇 #GoDCVAX
Hat tip @Sharpie510 Phase III trials for #glioblastoma patients: DCVax®-L is the ONLY proven therapy on this list that INCREASED SURVIVAL WITH STATISTICAL SIGNIFICANCE FOR BOTH NEWLY DIAGNOSED & RECURRENT #GBM. 💪 #FreezeYourTumor #GetDCVax #QualityOfLifeMatters $nwbo #dcvax

Phase III trials for #glioblastoma patients: DCVax®-L is the ONLY proven therapy on this list that INCREASED SURVIVAL WITH STATISTICAL SIGNIFICANCE FOR BOTH NEWLY DIAGNOSED & RECURRENT #GBM.
💪
#FreezeYourTumor
#GetDCVax
#QualityOfLifeMatters
$nwbo #dcvax
https://t.co/W0CKQzRIxI

The DCVax® Platform For All Solid Tumor Cancers
💪💪💪💪💪💪
#FreezeYourTumor
#GetDCVax
$nwbo #dcvax #glioblastoma #gbm #CancerVaccine #NonToxic
$NWBO Fantastic analysis that gets NWBO's situation exactly right. So if you want to update your NWBO insights or get acquainted with NWBO for the first time, this is required reading. https://t.co/cjchel1Wtf
Lisa, @LisainNJUSA
I was administered the DCVax in March of 2015. When my son was just three & a half months old. Dr. Liau saved my life with this scientific breakthrough in personalized immunotherapy.
He is the best thing that I’ve ever done in my life. She gave me two gifts, one was my life & the other was being a Father. I’m eternally grateful.
MHRA modified the DB to have the old PIP plan removed from search. Why now? The new/updated PIP plan for #DCVax-L was already reviewed & approved on 19/12/2023.
😉
https://t.co/oHRcsUl49H
#FreezeYourTumor
#GetDCVax
💪
$nwbo #glioblastoma #gbm #ForAllSolidTumors #CancerVaccine

#FreezeYourTumor
#GetDCVax
💪💪💪💪💪💪
$nwbo #dcvax #glioblastoma #gbm #NonToxic #CancerVaccine #ForAllSolidTumors $mrk $bmy $rhhby $azn $pfe $lly
📢📢$NWBO Acquires Advent Bioservices
https://t.co/ud6uYmesP7
$NWBO acquires Advent for $1.4m‼️
What does this accomplish?
➡️Management Team Expansion
Headcount just went from ~20 (ish) $NWBO employees to likely 100+ total employees. As you will see from Linda Powers comment at the ASM, a goal was to expand the management team. This is certainly a step in the right direction as it gives $NWBO a much larger pool of employees to take on expanded roles. Image 1 shows Advent's headcount at the end of '23 being 73 employees.
Linda Powers at 2023 ASM, held June 29, 2024, stated, in relevant part:
"And very dear to our hearts, we need to expand the management team. We need to expand the management team rather substantially. As you probably have guessed, and as we described in the proxy, each of the core members of the senior team has been wearing multiple hats, has been fulfilling multiple roles. And I mean, multiple roles that would each be normally a separate senior management person at other companies. And I'm really proud that we've been able to do that, but we need to we need to ramp up. We we've got tremendous opportunity, and we need to ramp up. So that is going to be a significant focus for us, as soon as we can achieve it. We wanna be highly selective, but we plan to substantially expand the management team." [1]
➡️A revenue steam to potentially help obtain standard bank financing
I believe this puts $NWBO in a position to obtain standard bank financing based off of Advent's revenue stream. This should help slow future dilution. As you can see, Advent's financial statement (Image 1) shows about $27.5m USD in revenue for '23, which was a 23% increase over '22. [2] A more modest 15% growth rate would give them nearly $32m in revenue for '24. I believe this should allow $NWBO to be eligible for standard bank financing. Hats off to the late Les Goldman for getting us to this point by tirelessly raising funds from retail and institutional investors.
➡️What was the value of Advent?
Recall, Cognate BioServices, Inc. sold for $875m on projected revenue of $140m for the year, a 6.25 multiple of revenue (I know, I know, a really quick and sloppy way of looking at it). [3] Say Advent is up to $40m in revenue and using the same multiple it gives a value of $250m.
➡️Big Money more receptive to investments
$NWBO has largely survived on the backs of retail investors to date. To attract more institutional investors and even potentially a buyer, $NWBO needed to undo some entanglements and become more transparent. While the Advent/$NWBO related party relationship was legal, it created some complicated dynamics that could have scared off the bigger investors. With today's acquisition of Advent, $NWBO just became more attractive to deeper pockets, whether investing or acquiring. This was the first, and the biggest, domino that had to fall in this regard. Great first step.
➡️Another deceptive Adam Feuerstein narrative bites the dust
See Image 3.
Mr. Feuerstein needs to, at the very least, add another line (or two) to his graphic:
Shareholder money -> NWBO -> Advent -> Linda Powers [insert additions] -> NWBO -> Shareholders
[1]https://t.co/3wNfuUaROE
[2]https://t.co/jlZS4ceQTA"08717711_aa_2025-03-04.pdf"&X-Amz-Signature=42d084f11a9fd893890cea368d750d572ffe089449d946904fda5f66a33ee978
[3]https://t.co/Jb2l9TNvmy
![hoffmann6383's tweet photo. 📢📢$NWBO Acquires Advent Bioservices
https://t.co/ud6uYmesP7
$NWBO acquires Advent for $1.4m‼️
What does this accomplish?
➡️Management Team Expansion
Headcount just went from ~20 (ish) $NWBO employees to likely 100+ total employees. As you will see from Linda Powers comment at the ASM, a goal was to expand the management team. This is certainly a step in the right direction as it gives $NWBO a much larger pool of employees to take on expanded roles. Image 1 shows Advent's headcount at the end of '23 being 73 employees.
Linda Powers at 2023 ASM, held June 29, 2024, stated, in relevant part:
"And very dear to our hearts, we need to expand the management team. We need to expand the management team rather substantially. As you probably have guessed, and as we described in the proxy, each of the core members of the senior team has been wearing multiple hats, has been fulfilling multiple roles. And I mean, multiple roles that would each be normally a separate senior management person at other companies. And I'm really proud that we've been able to do that, but we need to we need to ramp up. We we've got tremendous opportunity, and we need to ramp up. So that is going to be a significant focus for us, as soon as we can achieve it. We wanna be highly selective, but we plan to substantially expand the management team." [1]
➡️A revenue steam to potentially help obtain standard bank financing
I believe this puts $NWBO in a position to obtain standard bank financing based off of Advent's revenue stream. This should help slow future dilution. As you can see, Advent's financial statement (Image 1) shows about $27.5m USD in revenue for '23, which was a 23% increase over '22. [2] A more modest 15% growth rate would give them nearly $32m in revenue for '24. I believe this should allow $NWBO to be eligible for standard bank financing. Hats off to the late Les Goldman for getting us to this point by tirelessly raising funds from retail and institutional investors.
➡️What was the value of Advent?
Recall, Cognate BioServices, Inc. sold for $875m on projected revenue of $140m for the year, a 6.25 multiple of revenue (I know, I know, a really quick and sloppy way of looking at it). [3] Say Advent is up to $40m in revenue and using the same multiple it gives a value of $250m.
➡️Big Money more receptive to investments
$NWBO has largely survived on the backs of retail investors to date. To attract more institutional investors and even potentially a buyer, $NWBO needed to undo some entanglements and become more transparent. While the Advent/$NWBO related party relationship was legal, it created some complicated dynamics that could have scared off the bigger investors. With today's acquisition of Advent, $NWBO just became more attractive to deeper pockets, whether investing or acquiring. This was the first, and the biggest, domino that had to fall in this regard. Great first step.
➡️Another deceptive Adam Feuerstein narrative bites the dust
See Image 3.
Mr. Feuerstein needs to, at the very least, add another line (or two) to his graphic:
Shareholder money -> NWBO -> Advent -> Linda Powers [insert additions] -> NWBO -> Shareholders
[1]https://t.co/3wNfuUaROE
[2]https://t.co/jlZS4ceQTA"08717711_aa_2025-03-04.pdf"&X-Amz-Signature=42d084f11a9fd893890cea368d750d572ffe089449d946904fda5f66a33ee978
[3]https://t.co/Jb2l9TNvmy](https://pbs.twimg.com/media/GzX4wIKWEAAlA9G.png)
#Glioblastoma #gbm patients & their families can be proactive in getting the absolute best treatment possible. Don't accept a terrible prognosis with "Standard of Care".
#FreezeYourTumor
#GetDCVax
$nwbo #dcvax #NonToxic #CancerVaccine #ForAllSolidTumors
https://t.co/GFyEYxFXGo
@ThomasOwenMcCa1 @USAlpha1A2A3A4A @citsecurities @NYSE @metacollectiveG @TheLastWord @AP @DontheConDrumpf And refresh my memory again, Thomas... how many years since you received $NWBO #DCVAX?
Ten years?
And how old is your son?
Ten years old?
So, Dr Linda Liau and DCVAX not only saved your life, they gave your son his dad.
Only an asshat would criticize.
#DCVax-L extended median overall survival (mOS) to 19.3 months and survival after relapse to 13.2 months in newly diagnosed patients in a Phase 3 clinical trial in #glioblastoma (#GBM).
💪💪💪💪💪💪
#FreezeYourTumor
#GetDCVax
https://t.co/3juPH0uLDu
$nwbo

"...the phase III trial of DCVax-L, have initially demonstrated the great potential of vaccines in GBM treatment."
💪💪💪💪💪💪
#FreezeYourTumor
#GetDCVax
$nwbo #dcvax #glioblastoma #gbm #NonToxic #CancerVaccine #ForAllSolidTumors
https://t.co/6XHIcRuZnL
https://t.co/xnASgoXksV

Last Seen Hashtags on Sotwe
brosis
Seen from France
limbus_company #nsfw
Seen from United Kingdom
لانا_عقيل
Seen from Canada
تانجو_الطرية
Seen from Algeria
squirtng
ديوت_بدويٌّْ
Seen from United States
muslim #dl
Seen from United States
desihot_sardarboy
Seen from India
oddlywild
Seen from United States
ECUpdate
Seen from United States
Most Popular Users

Elon Musk 
@elonmusk
240.8M followers

Barack Obama 
@barackobama
118.8M followers

Cristiano Ronaldo 
@cristiano
114.5M followers

Donald J. Trump 
@realdonaldtrump
111.9M followers

Narendra Modi 
@narendramodi
107M followers

Rihanna 
@rihanna
98.7M followers

NASA 
@nasa
92.2M followers

Justin Bieber 
@justinbieber
91.8M followers

KATY PERRY 
@katyperry
90M followers

Taylor Swift 
@taylorswift13
84M followers

Lady Gaga 
@ladygaga
75.5M followers

Virat Kohli 
@imvkohli
73.4M followers

Kim Kardashian 
@kimkardashian
70.8M followers

YouTube 
@youtube
68.7M followers

Neymar Jr 
@neymarjr
66.4M followers

Bill Gates 
@billgates
65.2M followers

Selena Gomez 
@selenagomez
63.1M followers

The Ellen Show
@theellenshow
62.2M followers

CNN 
@cnn
61.7M followers

X 
@x
60.6M followers











![hoffmann6383's tweet photo. 📢📢$NWBO Acquires Advent Bioservices
https://t.co/ud6uYmesP7
$NWBO acquires Advent for $1.4m‼️
What does this accomplish?
➡️Management Team Expansion
Headcount just went from ~20 (ish) $NWBO employees to likely 100+ total employees. As you will see from Linda Powers comment at the ASM, a goal was to expand the management team. This is certainly a step in the right direction as it gives $NWBO a much larger pool of employees to take on expanded roles. Image 1 shows Advent's headcount at the end of '23 being 73 employees.
Linda Powers at 2023 ASM, held June 29, 2024, stated, in relevant part:
"And very dear to our hearts, we need to expand the management team. We need to expand the management team rather substantially. As you probably have guessed, and as we described in the proxy, each of the core members of the senior team has been wearing multiple hats, has been fulfilling multiple roles. And I mean, multiple roles that would each be normally a separate senior management person at other companies. And I'm really proud that we've been able to do that, but we need to we need to ramp up. We we've got tremendous opportunity, and we need to ramp up. So that is going to be a significant focus for us, as soon as we can achieve it. We wanna be highly selective, but we plan to substantially expand the management team." [1]
➡️A revenue steam to potentially help obtain standard bank financing
I believe this puts $NWBO in a position to obtain standard bank financing based off of Advent's revenue stream. This should help slow future dilution. As you can see, Advent's financial statement (Image 1) shows about $27.5m USD in revenue for '23, which was a 23% increase over '22. [2] A more modest 15% growth rate would give them nearly $32m in revenue for '24. I believe this should allow $NWBO to be eligible for standard bank financing. Hats off to the late Les Goldman for getting us to this point by tirelessly raising funds from retail and institutional investors.
➡️What was the value of Advent?
Recall, Cognate BioServices, Inc. sold for $875m on projected revenue of $140m for the year, a 6.25 multiple of revenue (I know, I know, a really quick and sloppy way of looking at it). [3] Say Advent is up to $40m in revenue and using the same multiple it gives a value of $250m.
➡️Big Money more receptive to investments
$NWBO has largely survived on the backs of retail investors to date. To attract more institutional investors and even potentially a buyer, $NWBO needed to undo some entanglements and become more transparent. While the Advent/$NWBO related party relationship was legal, it created some complicated dynamics that could have scared off the bigger investors. With today's acquisition of Advent, $NWBO just became more attractive to deeper pockets, whether investing or acquiring. This was the first, and the biggest, domino that had to fall in this regard. Great first step.
➡️Another deceptive Adam Feuerstein narrative bites the dust
See Image 3.
Mr. Feuerstein needs to, at the very least, add another line (or two) to his graphic:
Shareholder money -> NWBO -> Advent -> Linda Powers [insert additions] -> NWBO -> Shareholders
[1]https://t.co/3wNfuUaROE
[2]https://t.co/jlZS4ceQTA"08717711_aa_2025-03-04.pdf"&X-Amz-Signature=42d084f11a9fd893890cea368d750d572ffe089449d946904fda5f66a33ee978
[3]https://t.co/Jb2l9TNvmy](https://pbs.twimg.com/media/GzX4wIJXcAA1meO.png)
![hoffmann6383's tweet photo. 📢📢$NWBO Acquires Advent Bioservices
https://t.co/ud6uYmesP7
$NWBO acquires Advent for $1.4m‼️
What does this accomplish?
➡️Management Team Expansion
Headcount just went from ~20 (ish) $NWBO employees to likely 100+ total employees. As you will see from Linda Powers comment at the ASM, a goal was to expand the management team. This is certainly a step in the right direction as it gives $NWBO a much larger pool of employees to take on expanded roles. Image 1 shows Advent's headcount at the end of '23 being 73 employees.
Linda Powers at 2023 ASM, held June 29, 2024, stated, in relevant part:
"And very dear to our hearts, we need to expand the management team. We need to expand the management team rather substantially. As you probably have guessed, and as we described in the proxy, each of the core members of the senior team has been wearing multiple hats, has been fulfilling multiple roles. And I mean, multiple roles that would each be normally a separate senior management person at other companies. And I'm really proud that we've been able to do that, but we need to we need to ramp up. We we've got tremendous opportunity, and we need to ramp up. So that is going to be a significant focus for us, as soon as we can achieve it. We wanna be highly selective, but we plan to substantially expand the management team." [1]
➡️A revenue steam to potentially help obtain standard bank financing
I believe this puts $NWBO in a position to obtain standard bank financing based off of Advent's revenue stream. This should help slow future dilution. As you can see, Advent's financial statement (Image 1) shows about $27.5m USD in revenue for '23, which was a 23% increase over '22. [2] A more modest 15% growth rate would give them nearly $32m in revenue for '24. I believe this should allow $NWBO to be eligible for standard bank financing. Hats off to the late Les Goldman for getting us to this point by tirelessly raising funds from retail and institutional investors.
➡️What was the value of Advent?
Recall, Cognate BioServices, Inc. sold for $875m on projected revenue of $140m for the year, a 6.25 multiple of revenue (I know, I know, a really quick and sloppy way of looking at it). [3] Say Advent is up to $40m in revenue and using the same multiple it gives a value of $250m.
➡️Big Money more receptive to investments
$NWBO has largely survived on the backs of retail investors to date. To attract more institutional investors and even potentially a buyer, $NWBO needed to undo some entanglements and become more transparent. While the Advent/$NWBO related party relationship was legal, it created some complicated dynamics that could have scared off the bigger investors. With today's acquisition of Advent, $NWBO just became more attractive to deeper pockets, whether investing or acquiring. This was the first, and the biggest, domino that had to fall in this regard. Great first step.
➡️Another deceptive Adam Feuerstein narrative bites the dust
See Image 3.
Mr. Feuerstein needs to, at the very least, add another line (or two) to his graphic:
Shareholder money -> NWBO -> Advent -> Linda Powers [insert additions] -> NWBO -> Shareholders
[1]https://t.co/3wNfuUaROE
[2]https://t.co/jlZS4ceQTA"08717711_aa_2025-03-04.pdf"&X-Amz-Signature=42d084f11a9fd893890cea368d750d572ffe089449d946904fda5f66a33ee978
[3]https://t.co/Jb2l9TNvmy](https://pbs.twimg.com/media/GzX4wIFWEAAar28.png)




